To better investigate how Cx43 may modulate cisplatin sensitivity, we used the CRISPR technology to target the Y17 position of the Cx43 alleles of two lung cancer cell lines that naturally harbor either a KRASG12S (A549), or an EGFRL858R/T790Mmutation (NCI-H1975), in view of the fact that KRAS and EGFR mutations are present in 50% of lung adenocarcinomas and are mutually exclusive (Unni et al., 2015) (Fig. 1Aand1B). This evidence concerns the gene GJA1 and lung carcinoma.